Metabolic Reprogramming, Glyco-Lipotoxicity, and Epigenetic Memory Drive Cardiovascular Immune Damage
Background
Cardiovascular disease (CVD) remains a leading cause of mortality, with significant residual cardiovascular risk persisting even after intensive lipid-lowering therapies like statins. Current strategies, focused on LDL-C, often fail to address the underlying residual inflammatory risk (RIR), a potent predictor of major adverse cardiovascular events (MACE). Elevated high-sensitivity C-reactive protein (hsCRP) independently forecasts adverse outcomes, highlighting a critical gap in understanding and treating the inflammatory drivers of atherosclerosis beyond cholesterol management. This review explores these complex, interconnected mechanisms.
Study Design
This comprehensive review synthesizes current understanding of how metabolic reprogramming, glyco-lipotoxicity, and epigenetic memory contribute to cardiovascular immune damage. It critically examines the limitations of traditional CVD risk factor management and proposes a multidimensional framework for understanding cross-organ communication networks in disease progression. The authors analyze epidemiological data and mechanistic insights to highlight the persistent challenge of residual inflammatory risk and the need for a holistic approach beyond lipid-centric views.
Results
The review highlights that despite LDL-C reduction to guideline-recommended targets (e.g., <70 mg/dL>), the incidence of MACE remains persistently high, indicating significant residual cardiovascular risk. This phenomenon suggests that relying solely on lipid-centric treatment strategies is insufficient to halt atherosclerosis progression.
Residual inflammatory risk (RIR), typically signified by elevated high-sensitivity C-reactive protein (hsCRP), emerged as an independent and potent predictor of all-cause mortality, myocardial infarction, and stroke risk. For instance, hsCRP demonstrated superior predictive value for future cardiovascular events and mortality compared to LDL-C in high-risk patients. The paper emphasizes that metabolic dysregulation, beyond lipid levels, drives immune damage via mechanisms like
glyco-lipotoxicityandepigenetic memory, underscoring the need to address these underlying pathways.
Why It Matters
Shifting focus from solely lipid-centric to a holistic metabolic and inflammatory approach is crucial for improving CVD outcomes. This review underscores the need for novel therapeutic strategies targeting metabolic reprogramming, glyco-lipotoxicity, and epigenetic memory to address residual inflammatory risk. For clinicians and biohackers, it suggests that monitoring hsCRP and addressing systemic inflammation, beyond just cholesterol, is paramount. Future protocols may integrate interventions that modulate these underlying metabolic and epigenetic pathways to prevent and treat CVD, moving towards a more comprehensive understanding of disease pathogenesis.